Merrimack begins Phase II HERMIONE trial of MM-302 for breast cancer treatment
US-based Merrimack Pharmaceuticals has started the Phase II HERMIONE trial of MM-302, a HER2-targeted nanoliposomal encapsulation of doxorubicin, in combination with trastuzumab (Herceptin) to treat patients with HER2-positive locally advanced or met…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Nanotechnology | Pharmaceuticals